Pathophysiology of the metabolic syndrome: Implications for the cardiometabolic risks associated with type 2 diabetes

American Journal of the Medical Sciences

Volumn 343, Issue 1, 2012, Pages 13-16

  Leroith, Derek ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiometabolic risk factors; Metabolic syndrome; Type 2 diabetes

Indexed keywords

ADIPONECTIN; AMYLOID A PROTEIN; ANGIOTENSINOGEN; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ESTROGEN; FATTY ACID; FIBRIC ACID DERIVATIVE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; OMEGA 3 FATTY ACID; ORAL ANTIDIABETIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL OBESITY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFERENCE PAPER; DISEASE ASSOCIATION; DYSLIPIDEMIA; EPIDEMIC; EXERCISE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PREVALENCE; PREVENTION STUDY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; THROMBOSIS; WAIST CIRCUMFERENCE;

EID: 84855272505     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31823ea214     Document Type: Conference Paper

References (11)

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607. (Pubitemid 19004941)
2. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diab Med 1998;15:539-53. (Pubitemid 28319935)
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc 2001;285:2486-97.
4. Ramachandrappa S, Farooqi IS. Genetic approaches to understanding human obesity. J Clin Invest 2011;121:2080-6.
5. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 2004;33:351-75. (Pubitemid 38680634)
6. Reaven GM. Insulin resistance: the link between obesity and cardiovascular disease. Endocrinol Metab Clin North Am 2008;37:581-601.
7. Hwang J-H, Stein DT, Barzilai N, et al. Increased intrahepatic triglyceride is associated with peripheral insulin resistance: in vivo MR imaging and spectroscopy studies. Am J Physiol Endocrinol Metab 2007;293:E1663-9. (Pubitemid 350255117)
8. Paz K, Hemi R, LeRoith D, et al. A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem 1997;72:29911-8.
9. Brown CD, Higgins M, Donato KA, et al. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res 2000;8:605-19.
10. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005;28:1769-78. (Pubitemid 40923091)
11. Rousli N, Kerin PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008;93(11 suppl 1):S64-73.